AAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV Amino Acids · MW: 813.99
Amino Acids
AAGIGILTV
Molecular Weight
813.99
Half-life
Minutes to hours; subject to proteolysis
Research Score
4.4
Studies
89
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is AAGIGILTV?
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Key Benefits & Mechanisms
melanoma-associated epitope
supports CD8+ T-cell priming
used in therapeutic vaccine studies
Research Summary
A documented melanoma vaccine epitope used extensively in translational and clinical immunology research. It is frequently paired with adjuvants, dendritic-cell platforms, or altered peptide ligands to enhance immunogenicity.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesHPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Vaccine PeptidesWT1-126_134
Wilms Tumor 1 (WT1) peptide epitope RMFPNAPYL (aa 126-134)
A canonical HLA-A*0201-restricted WT1 peptide used in leukemia and solid-tumor vaccine studies. It is designed to elicit WT1-specific cytotoxic T cells against overexpressing tumor cells.
Vaccine Peptides